$32.66
6.21% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US23282W6057
Symbol
CYTK

Cytokinetics, Incorporated Stock price

$32.66
-5.27 13.89% 1M
-17.20 34.50% 6M
-14.38 30.57% YTD
-27.94 46.11% 1Y
-7.10 17.86% 3Y
+10.84 49.68% 5Y
+26.45 425.93% 10Y
Nasdaq, Closing price Tue, May 20 2025
+1.91 6.21%
ISIN
US23282W6057
Symbol
CYTK
Sector
Industry

Key metrics

Market capitalization $3.90b
Enterprise Value $3.75b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 195.26
P/S ratio (TTM) P/S ratio 202.94
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 412.21%
Revenue (TTM) Revenue $19.22m
EBIT (operating result TTM) EBIT $-565.64m
Free Cash Flow (TTM) Free Cash Flow $-407.57m
Cash position $938.59m
EPS (TTM) EPS $-5.31
P/E forward negative
P/S forward 165.33
EV/Sales forward 159.07
Short interest 15.85%
Show more

Is Cytokinetics, Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Cytokinetics, Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

22 Analysts have issued a Cytokinetics, Incorporated forecast:

19x Buy
86%
3x Hold
14%

Analyst Opinions

22 Analysts have issued a Cytokinetics, Incorporated forecast:

Buy
86%
Hold
14%

Financial data from Cytokinetics, Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
19 19
413% 413%
100%
- Direct Costs 9.50 9.50
29% 29%
49%
9.72 9.72
202% 202%
51%
- Selling and Administrative Expenses 218 218
39% 39%
1,133%
- Research and Development Expense 348 348
9% 9%
1,812%
-556 -556
15% 15%
-2,894%
- Depreciation and Amortization 9.50 9.50
29% 29%
49%
EBIT (Operating Income) EBIT -566 -566
14% 14%
-2,943%
Net Profit -615 -615
16% 16%
-3,201%

In millions USD.

Don't miss a Thing! We will send you all news about Cytokinetics, Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytokinetics, Incorporated Stock News

Neutral
GlobeNewsWire
3 days ago
Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions
Neutral
GlobeNewsWire
4 days ago
SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 5 employees, whose employment commenced in April and May, 2025, as a ...
Neutral
GlobeNewsWire
6 days ago
Second Annual Muscle Biology-Focused Research Symposium Highlighting Recent Innovations in the Field SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 30th, 2025 from 8:00 AM to 6:00 PM Pacific Time.
More Cytokinetics, Incorporated News

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Head office United States
CEO Robert Blum
Employees 498
Founded 1997
Website www.cytokinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today